<p>Ferdinandos Skoulidis, MD, PhD, discusses data on KRAS- mutated NSCLC from ASCO 2026 with Aakash Desai, MD, MPH, Fawzi F. Abu Rous, MD, and Eric K. Singhi, MD.</p>

Ferdinandos Skoulidis, MD, PhD, discusses data on KRAS- mutated NSCLC from ASCO 2026 with Aakash Desai, MD, MPH, Fawzi F. Abu Rous, MD, and Eric K. Singhi, MD.

What Do ASCO 2026 Data on NSCLC Co-mutations Mean for Practice?

LungCancerRx is a new podcast that features conversations among oncologists and patients. From tackling logistical obstacles to handling existential questions, these discussions aim to provide empowerment, knowledge, and hope across the lung cancer community. Eric K. Singhi, MD, a thoracic oncologist in Houston; Aakash Desai, MD, MPH, an assistant professor at the University of Alabama Birmingham’s O’Neal Cancer Center; and Fawzi Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit, cohost each episode. “We wanted to bridge the gap between provider communication and patient communication,” explains Dr. Singhi.

Share What Do ASCO 2026 Data on NSCLC Co-mutations Mean for Practice?

Sign up to save your podcasts

What Do ASCO 2026 Data on NSCLC Co-mutations Mean for Practice?

What Do ASCO 2026 Data on NSCLC Co-mutations Mean for Practice?

More shows like Lung Cancer Rx

Lung Cancer Considered